Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?

被引:43
作者
Capper, ER
Maskill, JK
Gordon, C
Blakemore, AIF [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Med Genet Sect, London SW7 2AZ, England
[2] Univ Birmingham, Dept Rheumatol, Birmingham, W Midlands, England
关键词
interleukin 1 receptor antagonist (IL-1ra); interleukin-10 (IL-10); interleukin-12 (IL-12); systemic lupus erythematosus (SLE);
D O I
10.1111/j.1365-2249.2004.02607.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several cytokines have been implicated individually in the pathogenesis of systemic lupus erythematosus (SLE) and some, including interleukin (IL)-10, IL-12 and IL-1ra are raised during flares of disease activity. Few studies have been directed at examining the interactions between these cytokines and how their combined profile relates to disease activity. We have examined serum levels of IL-10, IL-12 and IL-1ra in a cohort of SLE patients obtained from the Queen Elizabeth Hospital, Birmingham in cross-sectional and, in a smaller group, longitudinal analyses. In the cross-sectional study, there were significant correlations between levels of the three cytokines. There were also significant correlations between levels of each cytokine and measures of disease activity. IL-10 levels correlated with ESR, anti-dsDNA antibody titres and C3D, IL-12 levels with anti-dsDNA antibody titres and IL-1ra levels with ESR, anti-dsDNA antibody titres and C3D. IL-1ra levels also correlated with CRP. Circulating IL-10 and IL-1ra levels were higher in patients with SLE than in normal controls, although in this study group they did not reach significance. Circulating IL-12 levels were, however, significantly higher in SLE compared to controls. This was true both in patients with active disease and those sampled during a quiescent phase. These data add to the evidence that cytokines such as IL-10, IL-12 and IL-1ra are important in SLE pathogenesis. In a retrospective study of serial serum samples from seven patients, we found two patients whose cytokine profile was very different from the rest of the group. In most patients normalized IL-10, IL-12 and IL-1ra levels mirrored BILAG scores closely, but in these two patients, IL-10, IL-12 and IL-1ra levels did not fluctuate with disease activity. It is possible that there is a subgroup of SLE patients whose cytokine profile could be an important indicator of their pathology. In order to confirm this and determine the frequency of such patients this study needs to be repeated with a much larger subject group. The coexistence of patient groups with different patterns of cytokine activity might explain conflicting reports of associations of levels of particular cytokines with SLE. As the observed differences could reflect different aetiologies of SLE, this information could reveal valuable endophenotypes for genetic and functional studies of SLE and might, ultimately, inform therapeutic management.
引用
收藏
页码:348 / 356
页数:9
相关论文
共 41 条
[1]   Interleukin-1 receptor antagonist gene polymorphism, infectious burden, and coronary artery disease [J].
Auer, J ;
Berent, R ;
Weber, T ;
Eber, B .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (11) :1536-1537
[2]   INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM AS A DISEASE SEVERITY FACTOR IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BLAKEMORE, AIF ;
TARLOW, JK ;
CORK, MJ ;
GORDON, C ;
EMERY, P ;
DUFF, GW .
ARTHRITIS AND RHEUMATISM, 1994, 37 (09) :1380-1385
[3]   Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus [J].
Chang, DM .
IMMUNOLOGICAL INVESTIGATIONS, 1997, 26 (5-7) :649-659
[4]   Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis [J].
Criswell, LA ;
Amos, CI .
CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (02) :85-90
[5]   Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis [J].
Dewberry, R ;
Holden, H ;
Crossman, D ;
Francis, S .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (11) :2394-2400
[6]   Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice [J].
Elhage, R ;
Maret, A ;
Pieraggi, MT ;
Thiers, JC ;
Arnal, JF ;
Bayard, F .
CIRCULATION, 1998, 97 (03) :242-244
[7]   FAMILY STUDY OF THE MAJOR HISTOCOMPATIBILITY COMPLEX IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - IMPORTANCE OF NULL ALLELES OF C4A AND C4B IN DETERMINING DISEASE SUSCEPTIBILITY [J].
FIELDER, AHL ;
WALPORT, MJ ;
BATCHELOR, JR ;
RYNES, RI ;
BLACK, CM ;
DODI, IA ;
HUGHES, GRV .
BMJ-BRITISH MEDICAL JOURNAL, 1983, 286 (6363) :425-428
[8]   Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease [J].
Fiotti, N ;
Giansante, C ;
Ponte, E ;
Delbello, C ;
Calabrese, S ;
Zacchi, T ;
Dobrina, A ;
Guarnieri, G .
ATHEROSCLEROSIS, 1999, 145 (01) :51-60
[9]   Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease [J].
Francis, SE ;
Camp, NJ ;
Dewberry, RM ;
Gunn, J ;
Syrris, P ;
Carter, ND ;
Jeffery, S ;
Kaski, JC ;
Cumberland, DC ;
Duff, GW ;
Crossman, DC .
CIRCULATION, 1999, 99 (07) :861-866
[10]   Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus [J].
Gibson, AW ;
Edberg, JC ;
Wu, JM ;
Westendorp, RGJ ;
Huizinga, TWJ ;
Kimberly, RP .
JOURNAL OF IMMUNOLOGY, 2001, 166 (06) :3915-3922